Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest safe dose of the drug Velcade
(bortezomib) that can be given together with gemcitabine and pegylated liposomal doxorubicin
(Doxil) in the treatment of advanced cancer. The effect of this combination treatment on
tumor growth will also be studied.